PLRZ
Polyrizon Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$9.69
−3.15%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$9.70
From 52W high−43.59%
Volume26428.00
Market cap$23.52M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$9.70
From 52W high
−43.59%
Volume
26428.00
Market cap
$23.52M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
P/E (TTM)
—
RSI (14)
45.8
MomentumView details →
1D Return
−3.15%
YTD Return
+15.67%
SummaryUpdated Jun 1, 2026
Polyrizon Ltd. (NASDAQ:PLRZ) is an Israeli biotechnology company founded in 2005 and headquartered in Ra'anana, Israel. The company went public on October 29, 2024, making it one of the newest entrants to the public markets in the biotech sector. Polyrizon specializes in developing innovative medical device hydrogels delivered through nasal spray formulations designed to create protective barriers against viruses and allergens. As a pre-revenue biotech company, Polyrizon is currently in the development phase of its product pipeline, focusing on respiratory protection and allergy management solutions.
Similar companies
Latest newsMore news →
Polyrizon filed a U.S. patent application to expand intellectual property protection around its intranasal drug-delivery platform.15d agoPolyrizon enrolled the first patient in a U.S. clinical study evaluating the efficacy, safety and tolerability of its NASARIX (PL-14) Allergy Blocker in patients with seasonal allergic rhinitis.28d agoPolyrizon Ltd. entered into definitive agreements with a single institutional investor for a registered direct offering of ordinary shares and pre-funded warrants, plus a concurrent private placement of pre-funded and investor warrants, expecting aggregate gross proceeds of approximately $4.0 million.47d ago